US FDA to speed vape and pouch approvals, WSJ reports

• The FDA may simplify requirements for scientific studies and speed up review times to add flexibility for product authorizations
• Last month, the FDA approved three new 'JUUL2' e-cigarette products as part of a series of approvals for nicotine products viewed as alternatives to traditional cigarettes
• The Trump administration emphasized commitment to keeping nicotine from children and counterfeit vaping products off streets while providing safer alternatives for adults quitting smoking

Summary: US FDA to Speed Vape and Pouch Approvals

The U.S. Food and Drug Administration (FDA) is expected to announce measures within days to accelerate approval processes for vaping products and nicotine pouches, according to a Wall Street Journal report citing informed sources.

Key Developments:

• The FDA plans to revisit a 2021 rule governing new tobacco product applications
• Proposed changes include simplified requirements for scientific studies and faster review times
• The modifications aim to provide greater flexibility for product authorizations

Industry Context:

Tobacco companies have been lobbying the Trump administration and officials for a faster, clearer FDA authorization process. Last month, the FDA approved three new JUUL2 e-cigarette products, continuing a trend of authorizing nicotine products positioned as safer alternatives to traditional cigarettes.

Policy Position:

According to an HHS spokeswoman quoted in the WSJ report, "The Trump administration is committed to keeping nicotine out of the hands of kids, getting counterfeit vaping products off the streets and providing safer alternatives for adults who want to quit smoking cigarettes."

Historical Background:

During Trump's first term, his administration moved to remove flavored e-cigarettes from retail shelves to combat youth vaping, citing concerns that sweet flavors contributed to widespread nicotine addiction among children.

Market Implications:

The regulatory changes could significantly benefit vaping and nicotine pouch manufacturers by reducing time-to-market and compliance burdens, potentially expanding product offerings for adult consumers seeking cigarette alternatives. The FDA did not immediately respond to Reuters' request for comment, and the report could not be independently verified.